Detection of the T790M mutation usually involves a biopsy of the tumor tissue followed by genetic testing. Liquid biopsies that analyze circulating tumor DNA (ctDNA) in the blood are also increasingly used for this purpose. These methods provide a less invasive way to monitor for resistance mutations, allowing for timely adjustments in treatment.
